A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (ARTEMIS)
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Adverum Biotechnologies, Inc
Start Date
May 16, 2025
End Date
May 31, 2030
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Adverum Biotechnologies, Inc
Start Date
May 16, 2025
End Date
May 31, 2030